This website uses cookies

Read our Privacy policy and Terms of use for more information.

All the top Biotech & Pharma news in one daily newsletter.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

✅ The Good News ✅

THE GOOD
Approvals & Labels

Roche's Wilserdly (giredestrant) wins FDA approval for estrogen receptor-mutated hormone receptor-positive, HER2-negative advanced breast cancer
Small molecule, cancer, oral SERD, breast cancer, estrogen receptor, HR-positive HER2-negative - Read more

Pharmanovia, IMPACT Therapeutics' Sepalna (senaparib) wins European approval for advanced ovarian cancer following Ph3 success
Small molecule, cancer, PARP inhibitor, ovarian cancer, maintenance therapy, BRCA mutation - Read more

European Commission approves Ionis Pharmaceuticals' Tryngolza (olezarsen) for severe hypertriglyceridaemia based on Ph3 data
Antisense oligonucleotide, metabolic, olezarsen, hypertriglyceridaemia, APOC3 target - Read more

Novartis' Cosentyx (secukinumab) wins FDA approval for polymyalgia rheumatica as first anti-IL-17 biologic following Ph3 trial
Antibody, autoimmune, monoclonal antibody, polymyalgia rheumatica, IL-17 inhibitor, corticosteroid-refractory - Read more

FDA approves Teva Pharmaceuticals' Igalmi (dexmedetomidine) as first at-home treatment for agitation in schizophrenia, schizoaffective disorder, or bipolar disorder
Small molecule, neurological, dexmedetomidine, schizophrenia, bipolar disorder, agitation - Read more

THE GOOD
Business Development & Partnerships

BeOne Medicines expands CLL Society patient education partnership with $3M, three-year commitment
Patient education, oncology, digital health, AI/ML, milestone payments - Read more

Eli Lilly, Stipple Bio ink multi-target oncology licensing deal worth up to $5.9B
Licensing deal, oncology, antibody-drug conjugate, milestone payments, equity investment - Read more

VERDOT collaborates with Moderna on manufacturing units for investigational mRNA cancer therapy Intismeran
Manufacturing agreement, oncology, mRNA, bioprocessing, small molecule - Read more

Cilcare licenses two hearing disorder assets CIL005, CIL006 from Sanofi, terms undisclosed
Licensing deal, rare disease, autoimmune, small molecule, R&D - Read more

PRESENTED BY SCIENCE 2 SALES
Outbound and commercial intelligence built exclusively for selling into biopharma.

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

✅ More Good News ✅

THE GOOD
Clinical Trials

CG Oncology's (cretostimogene) hits Ph3 goal, cutting recurrence risk 68% in non-muscle invasive bladder cancer
Oncolytic virus, cancer, immunotherapy, bladder cancer, non-muscle invasive bladder cancer, BCG-unresponsive - Read more

Sellas' galinpepimut-S (GPS) cuts death risk 41% in Ph3 acute myeloid leukemia trial, FDA submission planned
Vaccine, cancer, cancer vaccine, acute myeloid leukemia, WT1 target, maintenance therapy - Read more

AriBio's AR1001 (AR1001) meets Ph3 endpoint, slowing cognitive decline 31% in early Alzheimer's disease monotherapy population
Small molecule, neurological, PDE5 inhibitor, Alzheimer's disease, monotherapy, oral therapy - Read more

THE GOOD
Company Launches

Marrow Therapeutics debuts with $173M Series A and B to develop in vivo blood disorder treatments
Rare disease, gene therapy, hematology, in vivo, preclinical, platform technology - Read more

THE GOOD
Fundraises

Isomorphic Labs raises $5B Series C, scaling AI drug design engine toward clinical trials
AI/ML platform, drug discovery, oncology, immunology, preclinical, platform-enabled - Read more

Commit Biologics closes $60M seed round to advance complement-powered immune engagers toward clinic
Complement biology, bispecific antibody, oncology, autoimmune, preclinical - Read more

THE GOOD
Lawsuits

AstraZeneca, Alexion win antitrust lawsuit over Soliris biosimilar delay allegations
Monoclonal antibody, rare disease, competitive, financial - Read more

THE GOOD
Mergers & Acquisitions

Medtronic acquires Contego Medical for $380M-plus to expand carotid artery and peripheral vascular disease portfolio
Medical device, cardiovascular, major transaction, strategic - Read more

PRESENTED BY YOU?
Get the attention of 3000+ Biotech & Pharma Professionals 🤩

sign me up 2 chainz GIF by MOST EXPENSIVEST

Gif: mostexpensivest on Giphy

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

❌ The Bad News ❌

THE BAD
Clinical Trials

Helus Pharma's HLP003 (deuterated psilocin) meets Ph3 primary endpoint in major depressive disorder despite serious adverse events
Small molecule, neurological, psychedelic therapy, major depressive disorder, psilocin, combination therapy - Read more

THE BAD
Regulatory

FDA issues warning letter to USV over contamination risks at India manufacturing facility
Sterile injectable, manufacturing, operational, regulatory, quality control - Read more

THE BAD
Strategic Plans

Leo Pharma delays 2026 IPO plans citing global market volatility and unfavorable listing conditions
Dermatology, financial, strategic, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Thanks for reading! -Anis

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here